A Phase 3 interventional study of Streptococcus salivarius 24SMBc + Strept. oralis 89a and fluticasone + mometasone in Allergy, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Federico II University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Hypersensitivity with a site in Italy — 1 open to participants now, 3 under way, none of them phase 3. Hypersensitivity · Italy.
Among the 43 studies in Hypersensitivity with a site in Italy, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2018, is one of 10 in phase 3, and was the 22nd registered.
1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →1 of the 43 studies in Hypersensitivity with a site in Italy is open now. Recruiting first, the newest first:
Cogent Biosciences, Inc. · Sites in Italy, United States, Australia and 11 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 73 across 692 interventional studies indexed under Hypersensitivity.
Median enrollment 237 across the 31 interventional studies, 148 across the 11 observational. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 43 have an industry lead sponsor. The 10 most frequent:
Federico II University is the lead sponsor of 366 studies on the registry; 60 are open to participants now.
Federico II University has 8 studies filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Hypersensitivity with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure. This condition represents a global health problem that affects 5 to 20% of the population. As with all allergic diseases, its prevalence in pediatric age has increased over the last 30 years, as shown by the results of the international epidemiological study International Study of Asthma and Allergies in Childhood (ISAAC) which shows that the overall prevalence is 8.5 % in children aged 6-7 and 14.6% in children aged 13-14. In Italy, on average, the prevalence stands at 17.6% in the 6-7 year age range and 31.3% in the 13-14 age range, demonstrating a growing trend. The allergic rhinoconjunctivitis undiagnosed and / or not treated properly can negatively affect the school activities and in general the quality of life of children and their parents, as well as having important socio-economic repercussions in terms of medical expenses, school absences and days of work lost by parents. Furthermore, the lack of therapeutic intervention can lead to an increased risk of complications in the medium and long term. Recent advances in the understanding of the mechanisms underlying the inflammation of the airways have led to an improvement of the therapeutic strategies for the management of allergic rhinoconjunctivitis: the four cornerstones of the approach to this pathology promoted by the European Academy of Allergy and Clinical Immunology (EAACI) include allergen removal, patient education, pharmacotherapy and specific immunotherapy. However, there is discordant evidence to support their efficacy in reducing the symptomatology of allergic rhinoconjunctivitis, with the need to resort to the invasive surgical approach in several cases. Therefore, the use of probiotics, defined as "live micro-organisms which, when administered in adequate quantities, confer an advantage for the organism" can be useful. The mechanisms by which probiotics or their components, for example DNA, proteins and peptides, exert such beneficial effects concern the regulation of the immune system, the antagonist action against potentially pathogenic microorganisms and the quantitative and qualitative modulation of the intestinal microbiota. In fact, recent clinical studies have demonstrated the protective effect of infections of the high respiratory tract in adults and recurrent average otitis in pediatric age of the Streptococcus salivarius 24SMBc and Streptococcus oralis 89a strains administered through nasal spray. These well-characterized probiotics were safe, tolerated and able to positively modulate the composition of the respiratory epithelial microbiota and the function of the immune system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
Combination Product: Streptococcus salivarius 24SMBc + Strept. oralis 89a
spray with fluticasone and mometasone
Combination Product: fluticasone + mometasone
spray with isotonic solution
Other: placebo
nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
Drug pages: Fluticasone · Mometasone Furoate
nasal spray based on fluticasone + mometasone
nasal spray based on isotonic solution
Total 5 Symptom Score (T5SS) from 0 to 15
Symptoms evaluation was made by the Total 5 Symptoms Score (T5SS), which includes the symptoms of nasal discharge (rhinorrhea), nasal congestion, itchy nose, sneezing, and itchy eyes. All symptoms were graded from 0 (absent) to 3 (very troublesome),with total scores ranging from 0-15.
Time frame: after 20 days of treatment
Pittsburgh Sleep Quality Index (PSQI) score
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the 7 component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.Traditionally, the items from the PSQI have been summed to create a total score to measure overall sleep quality.
Time frame: after 20 days of treatment
Evaluation of nasal microbiota composition
Evaluation of nasal microbiota composition with a nasal brushing and determination of phyla, class, order, family, genus
Time frame: after 20 days of treatment
Ran from Mar 2018 to primary completion in Sep 2018, 6 months.
Of 42 phase 3 interventional studies under Hypersensitivity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.